It is unclear whether IFN-I therapy is an effective benefit for patients with COVID-19, since SARS-CoV-2 may use ISG to increase infectivity, and it is not known whether the IFN response limits SARS-CoV-2 replication. The gene discussed is IFNA1; the disease is COVID-19.